从罗氏芬说明书变更看头孢曲松钠与含钙产品的合理使用

中国药物警戒 ›› 2015, Vol. 12 ›› Issue (4): 245-248.

• 医院药事管理与合理用药 • 上一篇下一篇

从罗氏芬说明书变更看头孢曲松钠与含钙产品的合理使用

关尚为¹，²,郑婷婷³,张威²*

1哈尔滨医科大学附属肿瘤医院药学部，黑龙江哈尔滨 150081;
2北京积水潭医院药剂科，北京 100035;
3北京大学药学院药事管理与临床药学系，北京100191

收稿日期:2014-12-05 出版日期:2015-04-08 发布日期:2015-07-27
通讯作者: 张威，女，副主任药师，药事管理与临床药学。
作者简介:关尚为，女，本科，药师，药品不良反应监测。

Rational Use of Ceftriaxone with Calcium Products from the Changes of Rocephin Label

GUAN Shang-wei¹,²,ZHENG Ting-ting³,ZHANG Wei²*

1Harbin Medical University Cancer Hospital, Heilongjiang Harbin 150081, China;
2Beijing Ji Shui Tan Hospital, Beijing 100035,China;
3Deparment of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China

Received:2014-12-05 Online:2015-04-08 Published:2015-07-27

摘要/Abstract

摘要： 目的为临床安全合理的使用头孢曲松钠与含钙产品提供依据。方法查阅在我国上市后已修订了六版的罗氏芬说明书，比较各版本说明书中提到头孢曲松钠与含钙产品的用法用量、不良反应、注意事项、禁忌部分的变更，了解头孢曲松钠与含钙产品的合理使用方法。结果从2009年第四版至最新版说明书中均明确标注了：“除新生儿，其他患者可进行罗氏芬和含钙输液的序贯给药，在两次输液之间必须用相容液体充分冲洗输液管。”结论同时静脉使用头孢曲松钠与含钙药物时可按说明书中方法正确序贯使用，但在特殊人群和情况下仍需谨慎。

关键词: 头孢曲松钠, 说明书, 乳酸钠林格注射液, 合理使用

Abstract: Objective To provide the information about the clinical safety and rational use of ceftriaxone with calcium products. Methods In order to gain the method of rational use of cetriaxone with calcium products, there is a need to compare the changes of usage and dosage, adverse reactions, attentions and compatibilities about the use of cetriaxone with calcium products in six different editions of rocephin label in our country. Results From the fourth edition in 2009 to the latest one, it has been marked clearly that rocephin and calcium-containing solutions may be administered sequentially of one another if the infusion lines are thoroughly flushed between infusions with a compatible fluid but except the neonatal. Conclusion According to the label, using the ceftriaxone with calcium products intravenously in sequential is allowed while it still needs to use carefully in special patients and conditions.

Key words: Key words：ceftriaxone, label, sodium lactate ringer's injection, rational use

中图分类号:

关尚为,郑婷婷,张威. 从罗氏芬说明书变更看头孢曲松钠与含钙产品的合理使用[J]. 中国药物警戒, 2015, 12(4): 245-248.

GUAN Shang-wei,,ZHENG Ting-ting,ZHANG Wei. Rational Use of Ceftriaxone with Calcium Products from the Changes of Rocephin Label[J]. Chinese Journal of Pharmacovigilance, 2015, 12(4): 245-248.

参考文献

[1] Mandell L A, Wunderink R G, Anzueto A,et al. Infectious Diseases Society of America/ American Thoracic Society consensus guidelines on the man-agement of community-acquired pneumonia in adults[J]. Clin Infect Dis，2007，44(Suppl 2):S27-72.
[2] Workowski K A, Berman S. Sexually transmitted diseases treatment guidelines[J]. MMWR Recomm Rep，2010.
[3] WHO. Management of the child with a serious infection or severe malnutrition: Guidelines for care at the first referral level in developing countries[B/OL].[2015-03-05]. http://www.whoint/maternal_child_adolescent/documents/fch_cah_00_1/en/.
[3] WHO. Dept.of Child and Adolescent Health and Development UNICEF. Management of the child with a serious infection or severe malnutrition: guidelines for care at the first-referral level in developing countries[M].Geneva:World Health Organization,2000:55.
[4] 中华医学会,中华医院管理学会药事管理专业委员会,中国药学会医院药学专业委员会,等.抗菌药物临床应用指导原则[J].中华医学杂志,2004,84(22):1857-1862.
[5] Schaed U B,Wedgwoed-Krucko J,Tschaeppeler H.Reversible ceftfia-xone-associated biliary pseudolithiasis in children[J].The Lancet,1988，2(8625):1411- 1413.
[6] Cochat P, Cochat N, Jouvenet M, et al. Ceftriaxone-associated nephrolithiasis[J]. Nephrol Dial Transplant, 1990, 5(11): 974-976.
[7] 许建文,付群.头孢曲松钠与含钙注射液不恰当配伍致药物反应3例[J].儿科药学杂志,2004,10(1):63-63.
[8] Shiffman M L, Keith F B, Moore E W. Pathogenesis of ceftriaxone-associated biliary sludge. In vitro studies of calcium-ceftriaxone binding and solubility[J]. Gastroenterology, 1990，99（6）:1772-1778.
[9] Lozanovski V J, Gucev Z, Avramoski V J, et al. Ceftriaxone associated urolithiasis in a child with hypercalciuria[J]. Hippokratia, 2011,15（2）:181-183.
[10] Chutipongtanate S,Thongboonkerd V.Ceftriaxone crystallization and its potential role in kidney stone formation[J].Biochemical and Biophysical Research Communications, 2011,406(3):396-402.
[11] Gargollo P C, Barnewolt C E, Pediatric ceftriaxone nephrolithiasis[J]. J Urol, 2005,173(2): 577-578.
[12] Nakai Y, Tokuyama E, Yoshida M, et al. Prediction of incompatibility of ceftriaxone sodium with calcium ions using the ionic product[J]. Yakugaku Zasshi,2010,130(1):95-102.
[13] 国家食品药品监督管理局. 关于修订头孢曲松钠说明书中警示语和注意事项的通知（急件）[EB/OL]. （2007-02-15）[2014-12-18].http://former.sfda.gov.cn/cmsweb/webportal/W473/A64019347.html.
[14] FDA.Information for Healthcare Professionals: Ceftriaxone (marketed as Rocephin) 9/2007 [EB/OL]. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProv-iders/DrugSafetyInformationforHeathcareProfessionals/ucm134328.htm,9/2007-18/12/2014.
[15] FDA.Information for Healthcare Professionals: Ceftriaxone(marketed as Rocephin and generics) [EB/OL].（2009-04-21）[2014-12-18].http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationfor-HeathcareProfessionals/ucm084263.htm.
[16] Bradley J S, Wassel R T, Lee L, et al. Intravenous Ceftriaxone and Calcium in the Neonate: Assessing the Risk for Cardiopulmonary Adverse Events[J]. Pediatrics,2009 ,123(4)：e609-613.
[17] 马红梅,张洪全,王艺红，等.注射用头孢曲松钠致假性结石的临床观察[J].基层医学论坛,2010,14(31):998-999.
[18] Palanduz A,Yalcin I,Tonquc E.Sonographic assessment of ceftriaxone-associated biliary pseudolithiasis in children[J].Journal of Clinical Ultrasound,2000，28(4):166-168.
[19] Avci Z,Koktener A,Uras N,et al. Nephrolithiasis associated with ceftriaxone therapy: a prospective study in 51 children[J]. Arch Dis Child，2004，89(11):1069-1072.
[20] 梅丹,傅强,王强，等.国产和进口口服钙制剂对体内钙水平影响的比较[J].中国药学杂志,1998, 33 (6):350-354.
[21] Cochat P, Cochat N, Jouvenet M, et al. Ceftriaxone-associated nephrolithiasis[J].Nephrol Dial Transplant ，1990，5(11):974-976.
[22] 王强,张凡,梅丹，等.关于修改头孢曲松说明书一事的探讨[J].中国医院药学杂志, 2008, 28(8): 659-662.
[23] Barry M，Brenner M D. Brenner & Rector's The Kidney[J]. American Journal of Kidney Diseases，2000，36(4):875-876.
[24] 张威,赵海涛,张晓琳，等.头孢曲松钠注射液致儿童假性结石2例[J].中国药物应用与监测,2011,8(2):126-127.
[25] Xiaoming Cong, Xiaojian Gu, Xizhao Sun, et al. Possible Function of Urinary pH and Citrate on the Ceftriaxone-induced Nephr-olithiasis[J]. Urology, 2014，83(1):63-67.

从罗氏芬说明书变更看头孢曲松钠与含钙产品的合理使用

Rational Use of Ceftriaxone with Calcium Products from the Changes of Rocephin Label

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	张建, 方慧华. 某院活血化瘀类中药注射剂使用评价标准建立的探索[J]. 中国药物警戒, 2024, 21(2): 185-189.
[2]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[3]	熊玮仪, 任经天. 抗肿瘤药说明书安全性信息上市后修订的考虑要点[J]. 中国药物警戒, 2024, 21(1): 94-97.
[4]	杨乐, 夏东胜, 王涛. 维生素B₆注射剂安全性风险分析[J]. 中国药物警戒, 2023, 20(7): 791-794.
[5]	孟康康, 刘赛月. 辅酶Q10注射剂上市后安全性分析[J]. 中国药物警戒, 2023, 20(7): 795-798.
[6]	秦桂兰, 周木子, 冀召帅, 毛乾泰, 艾超. 司美格鲁肽注射液致急性便秘1例分析[J]. 中国药物警戒, 2023, 20(7): 833-835.
[7]	陈诚, 邓莉, 刘松青, 杜倩, 奚鑫. 重庆市2015年至2020年药源性过敏性休克报告分析[J]. 中国药物警戒, 2023, 20(4): 460-464.
[8]	雷超, 乔萌, 陈子佳, 张强, 谢雁鸣, 王志飞. 中成药说明书安全性信息项修订的探讨与思考[J]. 中国药物警戒, 2023, 20(12): 1396-1400.
[9]	乔萌, 雷超, 陈子佳, 张强, 王志飞. 含细辛中成药说明书安全项信息现状分析及思考[J]. 中国药物警戒, 2023, 20(12): 1401-1406.
[10]	杨乐, 夏东胜, 王涛. 维生素B₂注射剂安全性风险分析[J]. 中国药物警戒, 2023, 20(11): 1256-1258.
[11]	钱佩佩, 曹凯, 徐炳欣, 应亚宾, 赵宁珂, 赵亮. 基于JADER数据库的奈玛特韦/利托那韦不良事件信号检测与分析[J]. 中国药物警戒, 2023, 20(10): 1154-1158.
[12]	张青霞, 江永贤, 董月鑫, 咸颖, 闫素英. 某三甲医院西药药品说明书贮藏条件风险分析及防范建议[J]. 中国药物警戒, 2022, 19(8): 913-918.
[13]	肖望重, 林聪, 黄莉, 戴冰, 高元峰. 中成药说明书用药禁忌调查分析[J]. 中国药物警戒, 2022, 19(4): 400-403.
[14]	朱旭婷, 任佳, 杭永付. 头孢曲松钠注射液致透析患者抗生素脑病3例分析[J]. 中国药物警戒, 2022, 19(3): 336-338.
[15]	赵建彬, 黄玉玲. 基于药品说明书和裁判文书的注射用帕瑞昔布用药风险点探索及应用[J]. 中国药物警戒, 2022, 19(11): 1250-1253.